Douglas Fleming
Head of Safety Sciences at BioNTech
- Role
- Head of Safety Sciences at BioNTech SE
- Location
- Princeton, NJ, US
- LinkedIn followers
- 500 followers
About Douglas Fleming
Physician and epidemiologist, clinical trialist and expert in Drug Safety. Doug received his BA in humanities and physics from Yale, and served as a Peace Corps Volunteer teacher in Kenya. He earned an MD from Yale Medical School, and did his residency in Internal Medicine at Mount Auburn Hospital of Harvard Medical School. He did his fellowship in Epidemiology with the Epidemic Intelligence Service of the United States Centers for Disease Control (CDC) in Atlanta, Georgia. Doug worked in public health for 15 years, teaching internal medicine at an inner-city health center, and later serving in CDC’s Global AIDS Program in Botswana (southern Africa), running clinical trials for HIV and TB medications. When he returned to the United States in 2007, he joined Bristol-Myers Squibb, where he worked for 5 years on clinical development in diabetes, and he developed epidemiologic tools for safety analyses. He joined Lexicon Pharmaceuticals in 2013 as Medical Lead for telotristat etiprate, and for 3 years led development of this new drug for a particular rare cancer (carcinoid tumor). The drug aims to reduce the severe effects of this tumor on the heart muscle. The drug’s clinical trials were successful, and were published in the Journal of Clinical Oncology. The drug subsequently was approved by FDA and EMA. In 2016, he returned to Bristol-Myers Squibb, where he led a group of physicians and epidemiologists who designed and built advanced epidemiological and clinical tools to detect and understand potential safety signals. In September 2020, he began a new role at BMS as Executive Director, Immunology & Fibrosis & CV, with Medical Capabilities / Medical Data Generation
Experience
Head of Safety Sciences
Apr 2022 — Present · New York, NY, US
Collaborates with multiple functions in Safety/PV, Risk Management, Clinical Development, and others to facilitate systematic and thorough assessment of safety for BioNTech medicines in development. To start on the 19th of April, 2022.
Education
Harvard Medical School
Medical Residency, Internal Medicine
1992 — 1994
CDC Epidemic Intelligence Service
Fellowship in Epidemiology and Public Health
1995 — 1997
Yale University
BA, Religious Studies and German Literature
1979 — 1984
Yale School of Medicine
Doctor of Medicine (MD), Medicine
1987 — 1991
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.